Anniek Strijdhorst

Tolerability of Adjuvant Nivolumab in Esophageal or Gastroesophageal Junction Cancer: A Real‐World Study

Michelle Koops van ’t Jagt, Anniek Strijdhorst, T.J. Huizer, Esther Albertien Kleibeuker et autres

Adjuvant nivolumab is approved for esophageal or gastroesophageal junction cancer after neoadjuvant chemoradiotherapy and resection. In the CheckMate-577 trial, Grade 3-5 nivolumab-related adverse events (AEs) occurred in 5% of patients, with early discontinuation due to toxicity in 9%. However, real-world data on …

nl (code pays fourni par la source)

QUANTIFYING CORONARY ARTERY CALCIFICATION USING ROUTINELY PERFORMED CONTRAST-ENHANCED ONCOLOGICAL CT SCANS: A PROOF-OF-CONCEPT STUDY

Thijs Dormans, Anniek Strijdhorst, Kate Froeling, Dimitris Karkalousos et autres

YEARS Algorithm for Diagnosis of Suspected Pulmonary Embolism in Patients With Cancer

Bram Akerboom, Emily S.L. Martens, Milou A.M. Stals, Rolf E. Brouwer et autres

Importance: Although the YEARS algorithm is a safe and efficient way to rule out acute pulmonary embolism (PE), robust evidence on its accuracy in patients with cancer is lacking, and current guidelines suggest proceeding directly to computed tomographic pulmonary angiography (CTPA). Objective: …

nl, us, it, fr, ch, es, be, de (code pays fourni par la source)

Imaging strategies for follow-up during adjuvant nivolumab in esophageal cancer: A multicenter retrospective cohort study

Tamara J. Huizer, Anniek Strijdhorst, Laurens V. Beerepoot, Mark I. van Berge Henegouwen et autres

INTRODUCTION: Adjuvant nivolumab improves disease-free survival in patients with esophageal or gastroesophageal junction cancer following neoadjuvant chemoradiotherapy and resection, but recurrence risk remains high. Optimal follow-up strategies for early detection of recurrence during nivolumab treatment are lacking. METHODS: In this multi-center, retrospective …

nl (code pays fourni par la source)

Antiphospholipid antibody formation during immune checkpoint inhibition in patients with cancer: a prospective cohort study

Anniek Strijdhorst, Dorien M. Salet, Jente M Schoenaker, Vossa van der Vegte et autres

Background: Immune checkpoint inhibitors (ICIs) significantly improve survival in many cancer types. However, ICIs are associated with an increased risk of venous and arterial thromboembolism, and the underlying mechanisms are incompletely understood. We hypothesized that ICI therapy may induce the development of …

nl (code pays fourni par la source)

Immune checkpoint inhibitor-induced myocarditis with atrioventricular conduction abnormalities: a case report

Anniek Strijdhorst, T.S.J. Opstal, Lourens Robbers, M. Labots et autres

Immune checkpoint inhibitors (ICIs) are increasingly used in the treatment of several cancer types, but can cause immune-related adverse events (irAEs) such as myocarditis. ICI-induced myocarditis is rare but potentially life threatening and may present with subtle or atypical symptoms, including conduction …

nl (code pays fourni par la source)

The immune checkpoint inhibitor avelumab increases aortic inflammation on [18F]FDG PET/CT: A retrospective cohort study

Anniek Strijdhorst, Reindert F. Oostveen, Mark P.A. Schilder, Arthur J.A.T. Braat et autres

BACKGROUND: Patients with cancer treated with immune checkpoint inhibitors (ICIs) are at increased risk of cardiovascular events. Preclinical studies suggest that this may result from inflammation-induced destabilization of atherosclerotic plaques. OBJECTIVE: To evaluate changes in vessel wall inflammation assessed using [18F]FDG positron …

nl, us (code pays fourni par la source)

Accelerated atherosclerosis associated with immune checkpoint inhibitors: a systematic review and meta-analysis of pre-clinical studies

Anniek Strijdhorst, Winnie G. Vos, Laura A. Bosmans, Kim E. Dzobo et autres

Abstract Background Patients with cancer treated with immune checkpoint inhibitors are at increased risk of myocardial infarction and ischemic stroke. The mechanism is incompletely understood but may involve accelerated atherosclerosis due to plaque inflammation. Pre-clinical studies may provide insight in these mechanisms. …

nl, us (code pays fourni par la source)

Immune checkpoint inhibition increases aortic inflammation on 18F-FDG PET/CT: a retrospective cohort study in patients with Merkel cell carcinoma receiving avelumab

Anniek Strijdhorst, Reindert F. Oostveen, Mary Schilder, Arthur J. A. T. Braat et autres

Abstract Background Patients with cancer treated with immune checkpoint inhibitors are at increased risk of cardiovascular events. Preclinical studies suggest that this may be driven by inflammation-induced acceleration of atherosclerosis. Objective We aimed to evaluate changes in vessel wall inflammation assessed using …

nl, us (code pays fourni par la source)

Accelerated atherosclerosis associated with immune checkpoint inhibitors: a systematic review and meta-analysis of pre-clinical studies

Anniek Strijdhorst, Winnie G. Vos, Laura A. Bosmans, Kim E. Dzobo et autres

BACKGROUND: Patients with cancer treated with immune checkpoint inhibitors are at increased risk of myocardial infarction and ischemic stroke. The mechanism is incompletely understood but may involve accelerated atherosclerosis due to enhanced inflammation. Pre-clinical studies may provide insight in these mechanisms. AIM: …

nl, us, be (code pays fourni par la source)

Shifting focus from venous to arterial thromboembolism in patients with cancer

Anniek Strijdhorst, Nick van Es

nl (code pays fourni par la source)

Severe osteoarticular and skin and soft tissue infection with Mycobacterium bovis following intravesical BCG instillation

Anniek Strijdhorst, L. Charlotte J. de Bree, Reinout van Crevel, Hanna K de Jong et autres

We describe the case of a 70-year-old immunocompromised patient who developed a severe disseminated Mycobacterium bovis BCG infection with several infected prosthetic joints and soft tissue abscesses following intravesical BCG instillation for bladder cancer. This case report addresses the risk of severe …

nl (code pays fourni par la source)